Compare BigBearai Holdings Inc (BBAI) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BigBearai Holdings Inc vs Zoetis Inc — how do they compare? BigBearai Holdings Inc trades at $3.26 (market cap $1.60B), while Zoetis Inc trades at $73.45 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 19.5× BigBearai Holdings Inc's market cap, and Zoetis Inc pays a 2.81% dividend while BigBearai Holdings Inc pays none. Which is the better fit depends on your goals.
| BBAI | ZTS | |
|---|---|---|
Market Cap | $1.60B | $31.14B |
Sector | Technology | Health |
52-Week High | $8.91 | $156.76 |
52-Week Low | $2.61 | $71.91 |
Enterprise Value | $1.30B | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BigBear.ai (BBAI) trades at $3.25, up 0.62% with a bullish technical signal. The company reported Q2 2026 revenue growth of 13% and margin expansion but missed EPS expectations. With a P/S ratio of 11.31 and negative profitability metrics, the stock faces fundamental challenges despite recent contract wins and product innovation in defense AI solutions.
Outlook remains cautious with persistent losses and cash burn offset by government contract momentum. Investment opportunity lies in defense AI specialization, while risks include execution challenges and competitive pressures. Analyst consensus shows 75% hold rating, reflecting balanced skepticism about near-term profitability.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
